Last reviewed · How we verify
low-dose rivaroxaban
low-dose rivaroxaban is a Factor Xa inhibitor Small molecule drug developed by China National Center for Cardiovascular Diseases. It is currently FDA-approved for Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease, Stroke prevention in atrial fibrillation (at reduced doses).
Low-dose rivaroxaban selectively inhibits Factor Xa in the coagulation cascade, reducing thrombin generation and blood clot formation at a lower dose than standard anticoagulation.
Rivaroxaban is used to treat conditions such as Pelvic Pain, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Acute Coronary Syndrome. It is a medication that works by inhibiting Factor Xa, a key component in the blood clotting process.
At a glance
| Generic name | low-dose rivaroxaban |
|---|---|
| Sponsor | China National Center for Cardiovascular Diseases |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the intrinsic and extrinsic coagulation pathways. At low doses, it provides antiplatelet and anticoagulant effects suitable for thromboprophylaxis and cardiovascular event reduction without the bleeding risk of full-dose anticoagulation. This formulation is designed to balance efficacy in preventing thrombotic events with improved safety.
Approved indications
- Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease
- Stroke prevention in atrial fibrillation (at reduced doses)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-dose rivaroxaban CI brief — competitive landscape report
- low-dose rivaroxaban updates RSS · CI watch RSS
- China National Center for Cardiovascular Diseases portfolio CI
Frequently asked questions about low-dose rivaroxaban
What is low-dose rivaroxaban?
How does low-dose rivaroxaban work?
What is low-dose rivaroxaban used for?
Who makes low-dose rivaroxaban?
What drug class is low-dose rivaroxaban in?
What development phase is low-dose rivaroxaban in?
What are the side effects of low-dose rivaroxaban?
What does low-dose rivaroxaban target?
Related
- Drug class: All Factor Xa inhibitor drugs
- Target: All drugs targeting Factor Xa
- Manufacturer: China National Center for Cardiovascular Diseases — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease
- Indication: Drugs for Stroke prevention in atrial fibrillation (at reduced doses)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing